Madrigal (MDGL) Files Rule 144 Notice for 7,616 RSU Shares
Rhea-AI Filing Summary
Madrigal Pharmaceuticals (MDGL) filed a Form 144 notifying the proposed sale of 7,616 common shares through Morgan Stanley Smith Barney on 08/21/2025, with an aggregate market value listed as $2,982,882.56 and 22,289,014 shares outstanding. The securities were acquired on 09/08/2024 as Restricted Stock Units from the issuer, with payment/vesting dated 09/08/2024. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- Securities were acquired as Restricted Stock Units, indicating the shares originated from compensation rather than an external purchase
- No other sales reported in the past three months, suggesting this is an isolated, planned disposition
Negative
- Proposed sale of insider shares totaling $2,982,882.56 may be perceived negatively by some investors
- Form lacks information on the identity and role of the seller, limiting context about the materiality of the sale
Insights
TL;DR: Insider plans to sell 7,616 RSU-derived shares valued at nearly $3.0M; transaction appears routine compensation-related disposal.
The Form 144 shows a proposed sale of 7,616 common shares acquired as Restricted Stock Units on 09/08/2024 and scheduled to be sold through Morgan Stanley Smith Barney on 08/21/2025 for an aggregate market value of $2,982,882.56. With 22,289,014 shares outstanding, this block represents a small fraction of the float. There were no other reported sales in the prior three months, suggesting this is an isolated, planned disposition rather than an accelerated dumping pattern. The filing contains the standard attestation regarding material non-public information.
TL;DR: This disclosure meets Rule 144 requirements; timing and RSU origin suggest a compensation-related sale, not an unexplained insider exit.
The notice identifies the source of the shares as RSUs issued by the company, which typically implies a vesting-triggered sale by an insider or affiliate. The use of a broker and the inclusion of the required attestation align with compliance norms for reporting under Rule 144. Absent additional context about the filer’s role or a pattern of sales, the filing reads as a compliance disclosure for a single planned sale rather than a governance red flag.